Melissa officinalis and Sleep: What Clinical Data Shows

Introduction

Burn care teams face a persistent challenge: managing the psychological burden that follows severe injury.

Melissa officinalis leaf extract has gained attention in formulation circles for its potential role in mood and sleep support applications. While most research has focused on extract forms, a clinical trial examined whether simple Melissa officinalis tea could offer meaningful benefits in one of healthcare's most stressful settings.

Researchers at Shahid Motahari Burn Hospital (Iran) conducted a 20-day controlled study with 36 burn patients, comparing daily Melissa officinalis tea consumption against black tea. The team measured anxiety levels, depression scores, sleep quality, and serum antioxidant markers—tracking outcomes that matter both clinically and from a formulation perspective.

This article breaks down what the data revealed, where the evidence holds up, and what formulation professionals should know about this traditional botanical's performance in a controlled clinical setting.

Key Takeaways

• A 36-patient clinical trial found that Melissa officinalis tea was associated with statistically significant reductions in anxiety scores compared to black tea over 20 days
• Depression scores improved significantly in the Melissa tea group, with the difference reaching statistical significance (P = 0.002)
• Sleep quality showed measurable improvement in participants consuming Melissa officinalis tea (P = 0.031)
• Serum antioxidant levels did not differ significantly between groups, suggesting the mood and sleep effects may operate through other pathways
• The study used a simple dried leaf infusion preparation—no standardized extract—which raises questions about bioactive consistency
• This is preliminary data from a single small trial in a specific clinical population; findings cannot be extrapolated to healthy individuals or other demographics
• The study did not investigate underlying mechanisms for the observed mood and sleep effects

What the Research Examined

The research team recruited 36 patients admitted to a burn care unit and divided them into two groups. The control group consumed black tea daily, while the experimental group received Melissa officinalis tea prepared from dried leaves.

Researchers measured four primary outcomes.Depression was assessed using the Beck Depression Inventory, and anxiety was evaluated using Kettles' anxiety questionnaire. Sleep quality was measured using the Petersburg Sleep Quality Index (PSQI). Serum total antioxidant capacity was analyzed via spectrophotometry at baseline and again after 20 days of intervention

The study design was straightforward: daily tea consumption over three weeks, with standardized assessment tools administered at the beginning and end of the intervention period. The experimental group received Melissa officinalis in tea-bag form at a dose of 2.5 g per serving, administered twice daily, for a total of 5 g dried leaf per day over the 20-day period. Specific preparation details such as water temperature and steeping time were not reported. No information was provided about cultivar, growing conditions, or standardisation of the leaves used.

Key Findings

Anxiety reduction. Participants consuming Melissa officinalis tea showed lower anxiety scores compared to the control group. The difference reached statistical significance (P = 0.023), suggesting the observed effect was unlikely due to chance alone in this sample.

Depression scores. The most pronounced difference appeared in depression measures. The Melissa tea group reported significantly improved depression scores compared to black tea consumers (P = 0.002). This was the strongest statistical finding in the trial.

Sleep quality improvements. The Petersburg Sleep Quality Index scores indicated better sleep in the Melissa officinalis group. The improvement was statistically significant (P = 0.031), though the study did not report specific sleep metrics such as time to fall asleep, sleep duration, or nighttime awakenings.

Antioxidant levels showed no change. Despite previous research suggesting antioxidant activity for Melissa officinalis compounds in laboratory studies, serum antioxidant measurements did not differ between the two groups (P = 0.96), nor within either group over time (experimental group: P = 0.931; control group: P = 0.591). The authors specifically attributed this to the tea-bag format: at 2.5 g per serving, the concentration of Melissa officinalis delivered may have been insufficient to produce measurable systemic antioxidant effects — a concentration level typically achieved only with standardized extracts. This distinction is directly relevant to formulators: tea-format preparations appear capable of supporting mood and sleep outcomes at this dose, but antioxidant positioning would likely require a more concentrated extract form.

What This Means for Nutraceutical and Functional Beverage Professionals

This study offers rare clinical data on a whole-plant preparation rather than a standardized extract. For formulators working in the mood support and sleep wellness space, several practical considerations emerge.

Simple preparations showed activity. The research used a basic dried leaf infusion—not a concentrated extract, not a standardized rosmarinic acid preparation. This suggests bioactive compounds in Melissa officinalis leaves may retain activity through traditional preparation methods. For beverage formulators or ready-to-drink tea developers, this represents a viable format worth exploring.

The antioxidant disconnect matters. Lab studies consistently show antioxidant activity in Melissa officinalis extracts, yet this clinical trial found no change in serum antioxidant markers. If you're formulating with Melissa primarily for its antioxidant properties, this data suggests that story may not translate to measurable outcomes in human trials. The mood and sleep effects appear independent of systemic antioxidant activity.

Stress context is important. This trial studied patients in an acute care setting experiencing significant physiological and psychological stress. The effect sizes observed here may not apply to healthy populations or mild sleep disruption. When evaluating ingredients for consumer wellness applications, it's critical to recognize that clinical populations often respond differently than the general public.

Dosing is partially defined. The study reported a dose of 2.5 g per tea-bag, administered twice daily (5 g/day). However, steeping time, water temperature, and leaf standardization data were not specified. Any brand citing this study should acknowledge these remaining preparation gaps when making formulation decisions. This lack of detail creates challenges for formulators attempting to replicate the research in product development. 

Quality considerations. With no mention of Melissa officinalis cultivar, growing conditions, harvest timing, or post-harvest processing, replicating these results depends on variables the study did not control or report. Sourcing managers should view this as a proof-of-concept study rather than a formulation blueprint.

Limitations and What We Don't Know Yet

This is a small study with significant limitations that must be understood before drawing broader conclusions.

Sample size and population. With only 36 participants, the study lacks the statistical power to detect small effects or rule out chance findings. Additionally, all participants were burn patients in a hospital setting—a highly specific population under acute stress. These results cannot be generalized to healthy individuals, people with chronic sleep issues unrelated to trauma, or other demographic groups.

No mechanistic investigation. The study measured outcomes but did not explore how Melissa officinalis tea produced these effects. The research did not assess GABAergic activity, neurotransmitter levels, cortisol response, or any other mechanism that might explain the observed anxiety, depression, and sleep improvements. Without mechanistic data, we cannot determine whether the effects are compound-specific, synergistic, or related to non-botanical factors.

Preparation and dosing variability. The study reported that Melissa officinalis was delivered as 2.5 g tea-bags twice daily. However, water temperature, steeping time, and leaf standardisation data were not reported. Different preparation methods yield different concentrations of bioactive compounds, and without these parameters, full reproducibility remains limited. Additionally, no information was provided about rosmarinic acid or other marker compound content in the dried leaf material used.

Placebo and expectation effects. While the study included a control group consuming black tea, there is no mention of blinding. Participants knew which tea they were receiving, which could have influenced self-reported outcomes for anxiety, depression, and sleep quality.

Duration is limited. A 20-day intervention period provides short-term data only. Long-term safety, sustained efficacy, and tolerance development were not assessed.

Missing biomarker data. The study measured total serum antioxidants but did not analyze specific Melissa officinalis compounds such as rosmarinic acid, caffeic acid derivatives, or other phenolic constituents. We don't know if the tea delivered consistent levels of known bioactive compounds, nor do we know which compounds (if any) correlated with outcomes.

Frequently Asked Questions

What is Melissa officinalis?

Melissa officinalis, commonly known as lemon balm, is a perennial herb in the mint family. It has been used traditionally in teas and extracts for calming and digestive support. Modern research has examined its potential effects on mood, sleep, and cognitive function.

How was Melissa officinalis tea prepared in this study?

The study used Melissa officinalis in tea-bag form at a dose of 2.5 g per tea-bag, administered twice daily (5 g total per day). Water temperature and steeping time were not specified in the published research. No standardization data for the dried leaf material was reported.

Can Melissa officinalis tea treat anxiety or insomnia?

No. This study found associations between Melissa officinalis tea consumption and improved anxiety, depression, and sleep scores in a specific clinical population. It does not establish tea as a treatment for anxiety disorders or insomnia. The findings are preliminary and limited to this small trial.

Why didn't antioxidant levels increase if Melissa officinalis has antioxidant compounds?

Laboratory studies show that Melissa officinalis compounds exhibit antioxidant activity in test tube settings. However, this clinical trial found no significant change in serum antioxidant markers (P = 0.96). The authors directly addressed this discrepancy: they attributed the lack of antioxidant effect to the tea-bag preparation format, noting that 2.5 g per serving was likely too low a concentration to raise systemic antioxidant levels — an effect more typically achieved with standardized concentrated extracts. For formulators, this means tea-format preparations at this dose may support mood and sleep outcomes but are unlikely to deliver measurable antioxidant benefits in human subjects.

What compounds in Melissa officinalis leaves are responsible for the effects observed?

The study did not analyze or identify specific bioactive compounds. Melissa officinalis is known to contain rosmarinic acid, caffeic acid derivatives, and various terpenes, but this research did not establish which (if any) of these contributed to the observed outcomes.

Is Melissa officinalis extract the same as Melissa officinalis tea?

No. Extracts are concentrated preparations that often standardize specific compounds, while tea is a simple water infusion of dried leaves. The concentration and profile of bioactive compounds differ significantly between the two forms. Research on extracts cannot be assumed to apply to tea, and vice versa.

How long does it take for Melissa officinalis to show effects on mood or sleep?

In this study, participants consumed Melissa officinalis tea daily for 20 days before final measurements were taken. The research does not clarify when effects first became noticeable or whether benefits required consistent use over the full duration.

Can this research be applied to functional beverage or supplement formulation?

The study provides preliminary evidence that dried Melissa officinalis leaves, prepared as tea, were associated with mood and sleep improvements in a clinical population. However, the lack of dosing, preparation, and quality details limits direct application to product development. Formulators interested in Melissa officinalis should consider this as early-stage data that warrants further investigation, not as a formulation roadmap.

Research Summary

• Research focus: Effects of Melissa officinalis tea on anxiety, depression, sleep quality, and serum antioxidant levels in burn patients
• Study type: Controlled clinical trial with 36 participants over 20 days
• Key findings: Statistically significant improvements in anxiety scores (P = 0.023), depression scores (P = 0.002), and sleep quality (P = 0.031) compared to black tea control group; no significant change in serum antioxidant levels (P = 0.96)
• Key limitations: Small sample size, highly specific clinical population, no mechanistic investigation, lack of preparation and dosing details, no blinding mentioned, short intervention duration
• Relevant professional applications: Preliminary evidence for Melissa officinalis tea in mood and sleep support formulations, particularly for stress-related applications; antioxidant positioning not supported by this clinical data; formulation and sourcing challenges due to missing preparation specifications

For Professionals: Quick Reference

• Study used whole dried leaves in tea-bag form (2.5 g per serving, twice daily = 5 g/day) — not extract; consider supply chain for food-grade dried Melissa officinalis standardised to rosmarinic acid content
• No standardization data reported; quality testing for rosmarinic acid and other markers recommended
• Effects observed in clinical stress population may not extrapolate to general wellness claims
• Antioxidant claims not supported by this human trial despite in vitro data
• Consider regulatory limitations on anxiety, depression, and sleep claims in target markets

‍

This article is based on published scientific research.

Content reviewed for scientific accuracy.

‍